Immunoglobulin produced by tumor-infiltrating B cell

Immunoglobulins produced by tumor-infiltrating B cells are antibodies specifically matured, diversified, and class-switched in the tumor microenvironment. These antibodies display clonality and may undergo affinity maturation and somatic hypermutation locally within TLS, interacting intricately with T cells, dendritic cells, and tumor antigens. In tumors, such immunoglobulins may mediate direct anti-tumor effects (e.g., through complement activation, ADCC) or contribute to local immunosuppression, and their pattern of expression often correlates with the presence of TLS and response to immunotherapies[1][2][3][5][6]. The concept does not refer to a single protein or receptor, but rather to a diverse set of antibodies produced specifically within malignant tissues, reflecting the dynamic interplay between the immune system and cancer cells. In summary, the entry "Tumor-specific B-cell immunoglobulin" is a descriptive umbrella for a heterogeneous population of antibodies within tumors, not a canonical molecular target suitable for direct drug action or structured database curation as a unique entity[3][4].

Other names

Antibody produced by tumor-infiltrating B cellIntratumoral immunoglobulinTumor-infiltrating B cell antibody